Related Experiment Video
Updated: Jun 4, 2025
07:00
Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine
Published on: February 26, 2019
9.4K
Oral GLP-1 Receptor Agonists for Weight Loss
Dana Krinsky1, Avraham Marcucci1, Jamie A Mullally2
1From the Department of Internal Medicine, New York Medical College/Westchester Medical Center, Valhalla, NY.
Cardiology in Review
|December 17, 2024
Summary
New oral GLP-1 receptor agonists, like oral semaglutide, offer promising alternatives to injectable obesity medications. Research explores their efficacy for weight loss and cardiovascular benefits in patients with obesity.
Area of Science:
- Pharmacology
- Endocrinology
- Metabolic Diseases
Background:
- Rising global obesity rates necessitate innovative pharmacotherapies.
- Current effective obesity treatments are primarily injectable, limiting accessibility.
- The development of oral antiobesity medications is a key unmet need.
Purpose of the Study:
- To review the literature on oral Glucagon-Like Peptide-1 (GLP-1) receptor agonists for obesity treatment.
- To focus on oral semaglutide's efficacy and FDA approval status.
- To examine the future impact of these oral agents on weight management and cardiovascular health.
Main Methods:
- Literature review of studies on oral GLP-1 receptor agonists.
- Analysis of data concerning semaglutide, danuglipron, and orforglipron for obesity.
- Examination of Food and Drug Administration (FDA) approval and clinical trial outcomes.
Main Results:
- Oral semaglutide is FDA-approved for type 2 diabetes and shows potential for obesity management.
- Other oral GLP-1 receptor agonists like danuglipron and orforglipron are under investigation.
- Efficacious oral options could significantly improve patient access to obesity pharmacotherapy.
Conclusions:
- Oral GLP-1 receptor agonists represent a significant advancement in obesity pharmacotherapy.
- Further research is needed to fully elucidate the long-term benefits for weight loss and cardiovascular disease.
- Oral formulations promise to enhance treatment accessibility and adherence for patients with overweight and obesity.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
297
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
297
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
155
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
155
01:06Oral Hypoglycemic Agents: Glinides
136
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
136
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
168
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
168
01:23Dipeptidyl Peptidase 4 Inhibitors
167
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
167
01:17Oral Hypoglycemic Agents: Sulfonylureas
186
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
186